Potential Role of CT Metrics in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension

Lung. 2015 Dec;193(6):911-8. doi: 10.1007/s00408-015-9813-8. Epub 2015 Oct 9.

Abstract

Purpose: Recent imaging studies demonstrated the usefulness of quantitative computed tomographic (CT) analysis assessing pulmonary hypertension (PH) in patients with chronic obstructive lung disease (COPD-PH). The aim of this study was to investigate whether it would be also valuable for predicting and evaluating the effect of pulmonary vasodilators in patients with COPD-PH.

Methods: We analyzed a correlation between the extent of cystic destruction (LAA%) and total cross-sectional areas of small pulmonary vessels less than 5 mm(2) (%CSA <5) in many CT slices from each of four COPD-PH patients before and after the initiation of pulmonary vasodilator. To evaluate those generalized data from patients with COPD, we evaluated multiple slices from 42 patients whose PH was not clinically suspicious. We also selected five PH patients with idiopathic interstitial pneumonia (IIP-PH) and analyzed serial changes of pulmonary artery enlargement (PA:A ratio).

Results: In 42 COPD patients without PH, LAA% had a statistically significant negative correlation with %CSA <5. However, three of four COPD-PH patients manifested no such correlation. In two patients, clinical findings were dramatically improved after the initiation of pulmonary vasodilator. Notably, LAA% and %CSA <5 in those patients correlated significantly after its treatment. In COPD-PH, the PA:A ratio was significantly decreased after the initiation of pulmonary vasodilator therapy (1.25 ± 0.13 vs. 1.13 ± 0.11, p = 0.019), but not in IIP-PH.

Conclusions: Our study demonstrates that the use of quantitative CT analysis is a plausible and beneficial tool for predicting and evaluating the effect of pulmonary vasodilators in patients with COPD-PH.

Keywords: Chronic obstructive pulmonary disease; Computed tomography; Pulmonary hypertension; Pulmonary vasodilator.

MeSH terms

  • Aged
  • Bosentan
  • Endothelin Receptor Antagonists / therapeutic use
  • Exercise Test
  • Female
  • Forced Expiratory Volume
  • Humans
  • Hypertension, Pulmonary / complications
  • Hypertension, Pulmonary / diagnostic imaging*
  • Hypertension, Pulmonary / drug therapy
  • Hypertension, Pulmonary / physiopathology
  • Male
  • Middle Aged
  • Pulmonary Artery / diagnostic imaging*
  • Pulmonary Artery / physiopathology
  • Pulmonary Diffusing Capacity
  • Pulmonary Disease, Chronic Obstructive / complications
  • Pulmonary Disease, Chronic Obstructive / diagnostic imaging*
  • Pulmonary Disease, Chronic Obstructive / physiopathology
  • Pulmonary Fibrosis / complications
  • Pulmonary Fibrosis / diagnostic imaging*
  • Pulmonary Fibrosis / physiopathology
  • Sildenafil Citrate / therapeutic use
  • Sulfonamides / therapeutic use
  • Tadalafil / therapeutic use
  • Tomography, X-Ray Computed
  • Vasodilator Agents / therapeutic use
  • Vital Capacity

Substances

  • Endothelin Receptor Antagonists
  • Sulfonamides
  • Vasodilator Agents
  • Tadalafil
  • Sildenafil Citrate
  • Bosentan